Clinical trial
Fludarabine, Carboplatin, and Topotecan in Treating Patients With…
NCT00005593 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005593 |
|---|---|
| Title | Fludarabine, Carboplatin, and Topotecan in Treating Patients With Relapsed/Refractory Acute Leukemia or Advanced Myelodysplastic Syndrome |
| Official title | Phase I Study of Fludarabine, Carboplatin, and Topotecan for Patients With Relapsed/Refractory Acute Leukemia and Advanced Myelodysplastic Syndromes |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | carboplatin, fludarabine phosphate, topotecan hydrochloride |
| Enrollment | 31 |
| Start date | Sep 1, 1998 |
| Primary completion | Apr 1, 2002 |
| Completion | Mar 1, 2003 |
| First posted | Feb 25, 2004 |
| Last update posted | Jun 11, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: